Cinclus Pharma Finished Final Phase III Patient Visits
The company has concluded safety monitoring for its linaprazan glurate study, with results expected in late 2026.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Will new drug trial results lead to better healthcare options for patients?
Cinclus Pharma has completed the final safety follow-up visit for the phase III HEEALING1 study of its candidate, linaprazan glurate. All planned patient visits for the global clinical trial are now concluded.
Why it matters
Completing patient visits clears the final hurdle for data collection in the phase III trial, setting the stage for topline results that will determine the drug's path toward regulatory consideration.
The firm has reached the end of the phase III HEEALING1 trial for linaprazan glurate after completing all planned patient visits. While trial operations have concluded, topline results remain pending until the fourth quarter of 2026.
The players
Cinclus Pharma
A pharmaceutical company focused on developing therapies for gastrointestinal diseases.
The details
The HEEALING1 study protocol required a series of safety follow-up visits to monitor participants, marking the final operational milestone of the clinical trial. With the completion of these visits, the company moves from the data collection phase to the final analysis of study results.
Timeline
September 29, 2026: Cinclus Pharma announced completion of the last patient visit.
Q4 2026: Topline study results are expected.
Market Landscape
This development marks the completion of a late-stage clinical trial within the standard drug development pipeline. The move represents a critical transition from patient enrollment and active monitoring to the final data analysis and reporting phase.
Operators in the pharmaceutical and biotech space should monitor the Q4 2026 reporting window for this trial outcome. The results will be a key performance indicator for the company's future market position.
The takeaway
Cinclus Pharma has now moved to the final data processing stage for linaprazan glurate. Analysts and competitors should calendar the Q4 2026 window for the release of topline study data.
What happens next
Topline study results for the HEEALING1 study are scheduled for release in Q4 2026.
Further reading
For broader insights on industry developments, visit the Healthcare section.
Source note: This article includes information reported by Redeye.
Live Poll
Will new drug trial results lead to better healthcare options for patients?
